The analyst's highest conviction call is to short the quantum computing sector, explicitly naming Quantumscape (QS) as a "great short" due to its perceived lack of fundamental value. Similarly, investors are advised to maintain or initiate short positions on Cassava Sciences (SAVA), as it is grouped with other speculative companies expected to decline. Following a failed Phase 2 trial, ImmuneBio (INMB) is viewed with extreme skepticism and its Alzheimer's drug is considered a failure. The company's plan to seek a partner is interpreted as a major red flag that it is abandoning development. The core thesis is to bet against these speculative biotech and tech stocks, which are seen as fundamentally overvalued.

ImmuneBio (INMB)

• The transcript contains a company call discussing the results of the Phase 2 "Mindful" trial for its Alzheimer's drug, Xpro.
• The company acknowledged that the trial did not meet its primary endpoints.
• Management is attempting to focus on a positive "spin" by highlighting a specific subgroup of patients: those with two or more biomarkers of inflammation. They claim Xpro appeared to "flatline cognition" in this specific group.
• The company plans to meet with the FDA to get approval for a new primary endpoint called EMAC for a potential Phase 3 trial, arguing it is a better measure for early Alzheimer's than the standard CDR endpoint.
• The company stated it will "seek the resources to move Xpro forward," which the podcast host interprets as looking for a partner.
• The host, Martin Shkreli, provides a highly critical counter-analysis:
  • He calls the company's presentation "typical face-saving."
  • He states that when a biotech company says it will advance a drug "with a partner," it is a euphemism for "giving up on the drug."
  • He believes there was "no benefit in the subgroup whatsoever" and calls the positive spin "a joke."

Takeaways

• The official company line is one of cautious optimism, focusing on a potential path forward in a specific patient population after a failed trial.
• However, the analyst's interpretation is extremely bearish. The failure to meet primary endpoints is seen as the most critical outcome.
• The mention of seeking a partner is viewed as a major red flag, signaling that the company may not have the resources or conviction to develop the drug on its own.
• Investors should be highly skeptical of the company's narrative and view the stock with extreme caution. The analyst clearly sees this as a failed drug.

Quantum Computing Sector & Quantumscape (QS)

• The analyst makes a broad, negative call on the entire quantum computing sector.
• He mentions Quantumscape (QS) specifically, noting it was down 12% on the day of the podcast.
• He states, "all the quantum stocks will be like immune someday. They are worse than immune."
• He believes the companies are fundamentally worthless and that "quantum computing stocks make INMB look legitimate," which is a harsh criticism given his view on INMB.
• He explicitly calls Quantum a "great short," implying a strong conviction that its stock price will fall significantly.

Takeaways

• The analyst holds an extremely bearish view on the quantum computing sector as a whole, believing it is a speculative bubble.
• He identifies Quantumscape (QS) and other quantum stocks as strong candidates for short-selling (betting that the stock price will go down).
• The investment thesis is that these companies are overvalued and will eventually collapse, though he notes it may be a trade that takes time to play out ("taking longer than I'd like").

Hewlett Packard (HPQ / HPE)

• The stock is mentioned in passing as a notable market mover.
• The analyst observes, "Hewlett Packard up 12," indicating a significant single-day price increase.

Takeaways

• This was a brief observation of a strong, positive price movement in Hewlett Packard.
• No further context or analysis was provided, so the insight is limited to acknowledging the stock's significant upward momentum on that day.

Cassava Sciences (SAVA)

• The analyst mentions Cassava Sciences as a direct comparison to ImmuneBio (INMB).
• He poses a rhetorical question: "Imagine if Inmune stayed at $10 Okay or cassava What would you do? Stay short just wait."

Takeaways

• The analyst groups Cassava (SAVA) with other companies he is highly skeptical of.
• The sentiment is clearly bearish.
• The advice implies that if the stock price remains elevated, the recommended strategy is to maintain a short position, indicating a belief that the stock is overvalued and will eventually decline.